Accelerating Clinical Trials

Commercially competitive with the CRO sector, Accelerating Clinical Trials (ACT) is a mission-driven organisation dedicated to blood cancers, working hand-in-hand with the UK haematology community to accelerate the delivery of commercial and investigator-initiated trials.

ACT was established with a clear goal: the provision of a sustainable infrastructure to conduct and accelerate specialised haemato-oncology trials in the UK, to improve the lives of people with blood cancer. The operating model is unique in the UK, and surplus income is reinvested for the future benefit of blood cancer patients.

This CEO appointment offers the unique opportunity to build and grow an extremely exciting business, that promises to challenge the status quo. Early engagement with ACT has been proven to help with clinical develop plans, study design and regulatory hurdles. The appointed candidate will have the scope to shape the landscape of clinical haemato-oncology (UK and international) through influencing at the cutting edge of clinical development, and working with the brightest minds in this area.

Saxton Bampfylde Ltd is acting as an employment agency advisor to ACT on this appointment. For further information about the role, including details about how to apply, please visit www.saxbam.com/appointments using reference TBJSA1. Alternatively telephone +44 (0)20 7227 0880 (during office hours). Applications should be received by noon on Friday 26 January 2024.